Share on StockTwits

Fate Therapeutics (NASDAQ:FATE) Insider Peter D. Flynn sold 3,305 shares of the company’s stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $7.00, for a total transaction of $23,135.00. Following the sale, the insider now directly owns 4,039 shares of the company’s stock, valued at approximately $28,273. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Fate Therapeutics (NASDAQ:FATE) traded down 0.86% on Wednesday, hitting $6.94. 12,903 shares of the company’s stock traded hands. Fate Therapeutics has a 52-week low of $4.30 and a 52-week high of $13.55. The stock has a 50-day moving average of $6.82 and a 200-day moving average of $7.27. The company’s market cap is $142.4 million.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.33) by $0.01. On average, analysts predict that Fate Therapeutics will post $-1.45 earnings per share for the current fiscal year.

Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.